The role of kinin receptors in cancer and therapeutic opportunities

Cancer Letters

Volumn 345, Issue 1, 2014, Pages 27-38

  da Costa, Patrícia L N ^a   Sirois, Pierre ^b   Tannock, Ian F ^c   Chammas, Roger ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Bradykinin; Cancer; Kallikrein kinin system; Kinin receptors; Renin angiotensin system

Indexed keywords

ACETYLLYSYLBRADYKININ[7 [3 (2 NAPHTHYL)ALANINE] 8 ISOLEUCINE 9 DEARGININE]; ANATIBANT; B 9870; BI 113823; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRECEPTIN; CAPTOPRIL; CARBOPLATIN; CU 201; DACARBAZINE; DELTIBANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; ETOPOSIDE; FASITIBANT; FOV 2304; ICATIBANT; KALLIKREIN; LOBRADIMIL; MEN 16132; MK 0686; NAVELBINE; PACLITAXEL; R 954; SAFOTIBANT; SSR 240612; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ASCITES TUMOR; AUTOCRINE EFFECT; BRAIN TUMOR; CANCER GROWTH; CARCINOGENESIS; DENDRITIC CELL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DRUG RECEPTOR BINDING; DRUG TARGETING; GLIOMA; HUMAN; ISCHEMIC HEART DISEASE; KALLIKREIN KININ SYSTEM; KNEE PAIN; LUNG CANCER; LUNG SMALL CELL CANCER; MACROPHAGE ACTIVATION; MELANOMA; METASTASIS INHIBITION; MIGRATION INHIBITION; NONHUMAN; OSTEOARTHRITIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOMA; SEPSIS; SHORT SURVEY; TOOTH PAIN; TRAUMATIC BRAIN INJURY; TUMOR CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ANGIOGENESIS; BRADYKININ; CANCER; KALLIKREIN-KININ SYSTEM; KININ RECEPTORS; RENIN-ANGIOTENSIN SYSTEM;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION;

EID: 84893805673     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.009     Document Type: Review

References (196)

1. AbdAlla S., Lother H., El Massiery A., Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 2001, 7:1003-1009.
2. AbdAlla S., Lother H., Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000, 407:94-98.
3. Ager E.I., Neo J., Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29:1675-1684.
4. Alexopoulou D.K., Papadopoulos I.N., Scorilas A. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clin. Biochem. 2013, 46:1453-1461.
5. Araujo R.C., Kettritz R., Fichtner I., Paiva A.C., Pesquero J.B., Bader M. Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol. Chem. 2001, 382:91-95.
6. Avgeris M., Mavridis K., Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol. Chem. 2012, 393:301-317.
7. Baba K., Yamaguchi O. Effects of bradykinin on cytoplasmic calcium and motility in murine bladder tumor cells. J. Urol. 2001, 165:259-262.
8. Balaguer J.M., Yu C., Byrne J.G., Ball S.K., Petracek M.R., Brown N.J., Pretorius M. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial. Clin. Pharmacol. Ther. 2013, 93:326-334.
9. Barki-Harrington L., Bookout A.L., Wang G., Lamb M.E., Leeb-Lundberg L.M., Daaka Y. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochem. J. 2003, 371:581-587.
10. Barki-Harrington L., Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J. Urol. 2001, 165:2121-2125.
11. Bathon J.M., Manning D.C., Goldman D.W., Towns M.C., Proud D. Characterization of kinin receptors on human synovial cells and upregulation of receptor number by interleukin-1. J. Pharmacol. Exp. Therap. 1992, 260:384-392.
12. Bawolak M.T., Touzin K., Moreau M.E., Desormeaux A., Adam A., Marceau F. Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul. Pept. 2008, 146:157-168.
13. Beck C., Piontek G., Haug A., Bas M., Knopf A., Stark T., Misslbeck M., Rudelius M., Reiter R., Brandstetter M., Pickhard A. The kallikrein-kinin-system in head and neck squamous cell carcinoma (HNSCC) and its role in tumour survival, invasion, migration and response to radiotherapy. Oral Oncol. 2012, 48:1208-1219.
14. 2+ and cell migration. J. Leukoc. Biol. 2007, 81:1445-1454.
15. Biyashev D., Tan F., Chen Z., Zhang K., Deddish P.A., Erdos E.G., Hecquet C. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1244-H1250.
16. Blaes N., Girolami J.P. Targeting the 'Janus face' of the B2-bradykinin receptor. Expert Opin. Therap. Targets 2013, 17:1145-1166.
17. Blaukat A., Micke P., Kalatskaya I., Faussner A., Muller-Esterl W. Downregulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H1909-H1916.
18. Bockmann S., Paegelow I. Kinins and kinin receptors: importance for the activation of leukocytes. J. Leukoc. Biol. 2000, 68:587-592.
19. Bogle R.G., Coade S.B., Moncada S., Pearson J.D., Mann G.E. Bradykinin and ATP stimulate l-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem. Biophys. Res. Commun. 1991, 180:926-932.
20. Bouthillier J., Deblois D., Marceau F. Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo. Br. J. Pharmacol. 1987, 92:257-264.
21. Bozo E., Eles J., Keseru G.M. Bradykinin B1 receptor antagonists: a patent update 2009-2012. Expert Opin. Ther. Pat. 2012, 22:1443-1452.
22. Brechter A.B., Persson E., Lundgren I., Lerner U.H. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases. Bone 2008, 43:72-83.
23. Bujalska M., Tatarkiewicz J., Gumulka S.W. Effect of bradykinin receptor antagonists on vincristine- and streptozotocin-induced hyperalgesia in a rat model of chemotherapy-induced and diabetic neuropathy. Pharmacology 2008, 81:158-163.
24. Bunn P.A., Dienhart D.G., Chan D., Tagawa M., Jewett P. Effects of neuropeptides on human lung and breast cancer cells. J. Natl. Cancer Inst. Monogr. 1992, 145-151.
25. Busse R., Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes 1996, 45(Suppl 1):S8-13.
26. Calixto J.B., Cabrini D.A., Ferreira J., Campos M.M. Kinins in pain and inflammation. Pain 2000, 87:1-5.
27. Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., Campos M.M. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J. Pharmacol. 2004, 143:803-818.
28. Chan D., Gera L., Stewart J., Helfrich B., Verella-Garcia M., Johnson G., Baron A., Yang J., Puck T., Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc. Natl. Acad. Sci. USA 2002, 99:4608-4613.
29. Chan D.C., Gera L., Stewart J.M., Helfrich B., Zhao T.L., Feng W.Y., Chan K.K., Covey J.M., Bunn P.A. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin. Cancer Res. 2002, 8:1280-1287.
30. Charignon D., Spath P., Martin L., Drouet C. Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin. Pharmacother. 2012, 13:2233-2247.
31. Chee J., Naran A., Misso N.L., Thompson P.J., Bhoola K.D. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol. Chem. 2008, 389:1225-1233.
32. Chee J., Naran A., Misso N.L., Thompson P.J., Bhoola K.D. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol. Chem. 2008, 389:1225-1233.
33. Chee J., Singh J., Naran A., Misso N.L., Thompson P.J., Bhoola K.D. Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma. Biol. Chem. 2007, 388:1235-1242.
34. Chen Z., Deddish P.A., Minshall R.D., Becker R.P., Erdos E.G., Tan F. Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2006, 20:2261-2270.
35. Clements J., Mukhtar A. Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology 1997, 36:217-220.
36. Correa M., Machado J., Carneiro C.R., Pesquero J.B., Bader M., Travassos L.R., Chammas R., Jasiulionis M.G. Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. Int. J. Cancer 2005, 114:356-363.
37. Costa-Neto C.M., Dillenburg-Pilla P., Heinrich T.A., Parreiras-e-Silva L.T., Pereira M.G., Reis R.I., Souza P.P. Participation of kallikrein-kinin system in different pathologies. Int. Immunopharmacol. 2008, 8:135-142.
38. Cote J., Savard M., Neugebauer W., Fortin D., Lepage M., Gobeil F. Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors. Cancer Biol. Ther. 2013, 14.
39. Couture R., Harrisson M., Vianna R.M., Cloutier F. Kinin receptors in pain and inflammation. Eur. J. Pharmacol. 2001, 429:161-176.
40. Cuddapah V.A., Turner K.L., Seifert S., Sontheimer H. Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3.1 and ClC-3. J. Neuroscience: Off. J. Soc. Neuroscience 2013, 33:1427-1440.
41. Dabire H., Barthelemy I., Blanchard-Gutton N., Sambin L., Sampedrano C.C., Gouni V., Unterfinger Y., Aguilar P., Thibaud J.L., Ghaleh B., Bize A., Pouchelon J.L., Blot S., Berdeaux A., Hittinger L., Chetboul V., Su J.B. Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS. Basic Res. Cardiol. 2012, 107:240.
42. Davis A.J., Perkins M.N. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br. J. Pharmacol. 1994, 113:63-68.
43. Deblois D., Bouthillier J., Marceau F. Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to des-Arg9-bradykinin. Br. J. Pharmacol. 1988, 93:969-977.
44. Dillenburg-Pilla P., Maria A.G., Reis R.I., Floriano E.M., Pereira C.D., De Lucca F.L., Ramos S.G., Pesquero J.B., Jasiulionis M.G., Costa-Neto C.M. Activation of the kinin B1 receptor attenuates melanoma tumor growth and metastasis. PLoS One 2013, 8:e64453.
45. Dlamini Z., Bhoola K. Esophageal cancer in African blacks of Kwazulu Natal. South Africa: an epidemiological brief. Ethnicity Disease 2005, 15:786-789.
46. Dlamini Z., Bhoola K.D. Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J. Clin. Pathol. 2005, 58:915-922.
47. Dominek P., Campagnolo P., H-Zadeh M., Krankel N., Chilosi M., Sharman J.A., Caporali A., Mangialardi G., Spinetti G., Emanueli C., Pignatelli M., Madeddu P. Role of human tissue kallikrein in gastrointestinal stromal tumour invasion. Br. J. Cancer 2010, 103:1422-1431.
48. Downward J., de Gunzburg J., Riehl R., Weinberg R.A. P21ras-induced responsiveness of phosphatidylinositol turnover to bradykinin is a receptor number effect. Proc. Natl. Acad. Sci. USA 1988, 85:5774-5778.
49. Drube S., Liebmann C. In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist. Br. J. Pharmacol. 2000, 131:1553-1560.
50. Ehrenfeld P., Conejeros I., Pavicic M.F., Matus C.E., Gonzalez C.B., Quest A.F., Bhoola K.D., Poblete M.T., Burgos R.A., Figueroa C.D. Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Lett. 2011, 301:106-118.
51. Ehrenfeld P., Matus C.E., Pavicic F., Toledo C., Nualart F., Gonzalez C.B., Burgos R.A., Bhoola K.D., Figueroa C.D. Kinin B1 receptor activation turns on exocytosis of matrix metalloprotease-9 and myeloperoxidase in human neutrophils: involvement of mitogen-activated protein kinase family. J. Leukoc. Biol. 2009, 86:1179-1189.
52. Ehrenfeld P., Millan C., Matus C.E., Figueroa J.E., Burgos R.A., Nualart F., Bhoola K.D., Figueroa C.D. Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J. Leukoc. Biol. 2006, 80:117-124.
53. Elliott P.J., Hayward N.J., Dean R.L., Bartus R.T. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology 1996, 33:205-208.
54. Emerich D.F., Dean R.L., Snodgrass P., Lafreniere D., Agostino M., Wiens T., Xiong H., Hasler B., Marsh J., Pink M., Kim B.S., Perdomo B., Bartus R.T. Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J. Pharmacol. Exp. Ther. 2001, 296:632-641.
55. Enquist J., Sanden C., Skroder C., Mathis S.A., Leeb-Lundberg L.M. Kinin-stimulated B1 receptor signaling depends on receptor endocytosis whereas B2 receptor signaling does not. Neurochem. Res. 2013.
56. Erdos E.G., Tan F., Skidgel R.A. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010, 55:214-220.
57. Esseghir S., Reis-Filho J.S., Kennedy A., James M., O'Hare M.J., Jeffery R., Poulsom R., Isacke C.M. Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J. Pathol. 2006, 210:420-430.
58. Fein A.M., Bernard G.R., Criner G.J., Fletcher E.C., Good J.T., Knaus W.A., Levy H., Matuschak G.M., Shanies H.M., Taylor R.W., Rodell T.C. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and sepsis study group. JAMA, J. Am. Med. Assoc. 1997, 277:482-487.
59. Fernandes P.D., Gomes Nde M., Sirois P. The bradykinin B1 receptor antagonist R-954 inhibits Ehrlich tumor growth in rodents. Peptides 2011, 32:1849-1854.
60. Figueroa C.D., Ehrenfeld P., Bhoola K.D. Kinin receptors as targets for cancer therapy. Expert Opin. Therap. Targets 2012, 16:299-312.
61. Fox A., Kaur S., Li B., Panesar M., Saha U., Davis C., Dragoni I., Colley S., Ritchie T., Bevan S., Burgess G., McIntyre P. Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br. J. Pharmacol. 2005, 144:889-899.
62. Fujita M., Andoh T., Ohashi K., Akira A., Saiki I., Kuraishi Y. Roles of kinin B(1) and B(2) receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. Eur. J. Pain 2009.
63. Gomis A., Meini S., Miralles A., Valenti C., Giuliani S., Belmonte C., Maggi C.A. Blockade of nociceptive sensory afferent activity of the rat knee joint by the bradykinin B2 receptor antagonist fasitibant. Osteoarthr. Cartilage/OARS, Osteoarthr. Res. Soc. 2013, 21:1346-1354.
64. Gougat J., Ferrari B., Sarran L., Planchenault C., Poncelet M., Maruani J., Alonso R., Cudennec A., Croci T., Guagnini F., Urban-Szabo K., Martinolle J.P., Soubrie P., Finance O., Le F.G. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl ]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]pheny l)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004, 309:661-669.
65. Greco S., Elia M.G., Muscella A., Romano S., Storelli C., Marsigliante S. Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture. J. Endocrinol. 2005, 186:291-301.
66. Greco S., Muscella A., Elia M.G., Romano S., Storelli C., Marsigliante S. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J. Cell Physiol. 2004, 201:84-96.
67. Greco S., Storelli C., Marsigliante S. Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J. Endocrinol. 2006, 188:79-89.
68. Guevara-Lora I., Blonska B., Faussner A., Kozik A. Kinin-generating cellular model obtained from human glioblastoma cell line U-373. Acta Biochim. Pol. 2013.
69. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
70. Hanif K., Bid H.K., Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens. Res.: Off. J. Jpn. Soc. Hypertens. 2010, 33:11-21.
71. Hansen J.L., Hansen J.T., Speerschneider T., Lyngso C., Erikstrup N., Burstein E.S., Weiner D.M., Walther T., Makita N., Iiri T., Merten N., Kostenis E., Sheikh S.P. Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R/B2R heterodimer?. J. Biol. Chem. 2009, 284:1831-1839.
72. Hawkinson J.E., Szoke B.G., Garofalo A.W., Hom D.S., Zhang H., Dreyer M., Fukuda J.Y., Chen L., Samant B., Simmonds S., Zeitz K.P., Wadsworth A., Liao A., Chavez R.A., Zmolek W., Ruslim L., Bova M.P., Holcomb R., Butelman E.R., Ko M.C., Malmberg A.B. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. J. Pharmacol. Exp. Therap. 2007, 322:619-630.
73. Heasley L.E. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001, 20:1563-1569.
74. Ikeda Y., Hayashi I., Kamoshita E., Yamazaki A., Endo H., Ishihara K., Yamashina S., Tsutsumi Y., Matsubara H., Majima M. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res. 2004, 64:5178-5185.
75. Ishihara K., Hayash I., Yamashina S., Majima M. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn. J. Pharmacol. 2001, 87:318-326.
76. Ishihara K., Kamata M., Hayashi I., Yamashina S., Majima M. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int. Immunopharmacol. 2002, 2:499-509.
77. Kast R.E. Epithelial ovarian cancer: a feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, Icatibant, imiquimod peritoneal lavage, and plerixafor. J. Cancer Therap. Res. 2012, 1.
78. Kim J.H., Jain D., Tliba O., Yang B., Jester W.F., Panettieri R.A., Amrani Y., Pure E. TGF-beta potentiates airway smooth muscle responsiveness to bradykinin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L511-L520.
79. Kontos C.K., Chantzis D., Papadopoulos I.N., Scorilas A. Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Lett. 2013, 330:106-112.
80. Kontos C.K., Mavridis K., Talieri M., Scorilas A. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects. Thromb. Haemost. 2013, 110:450-457.
81. Kramarenko, Morinelli T.A., Bunni M.A., Raymond J.R., Garnovskaya M.N. The bradykinin B(2) receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines. Cancer Manage. Res. 2012, 4:195-205.
82. Kugaevskaia E.V., Eliseeva Iu E. ACE inhibitors-activators of kinin receptors. Biomeditsinskaia Khimiia 2011, 57:282-299.
83. Kuhr F., Lowry J., Zhang Y., Brovkovych V., Skidgel R.A. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010, 44:145-154.
84. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005, 57:27-77.
85. Lembeck F., Griesbacher T., Eckhardt M., Henke S., Breipohl G., Knolle J. New, long-acting, potent bradykinin antagonists. Br. J. Pharmacol. 1991, 102:297-304.
86. Lin C.C., Hsieh H.L., Shih R.H., Chi P.L., Cheng S.E., Chen J.C., Yang C.M. NADPH oxidase 2-derived reactive oxygen species signal contributes to bradykinin-induced matrix metalloproteinase-9 expression and cell migration in brain astrocytes. Cell Commun. Signal.: CCS 2012, 10:35.
87. Loiola R.A., Reis F.C., Kawamoto E.M., Scavone C., Abdalla D.S., Fernandes L., Pesquero J.B. Role of vascular Kinin B1 and B2 receptors in endothelial nitric oxide metabolism. Peptides 2011, 32:1700-1705.
88. Lu D.Y., Leung Y.M., Huang S.M., Wong K.L. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J. Cell. Biochem. 2010, 110:141-150.
89. Ma Q.P., Heavens R. Basal expression of bradykinin B(1) receptor in the spinal cord in humans and rats. NeuroReport 2001, 12:2311-2314.
90. Ma T., Liu L., Wang P., Xue Y. Evidence for involvement of ROCK signaling in bradykinin-induced increase in murine blood-tumor barrier permeability. J. Neurooncol. 2012, 106:291-301.
91. Madeddu P., Emanueli C., El-Dahr S. Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling, Nature clinical practice. Nephrology 2007, 3:208-221.
92. Maeda H., Matsumura Y., Kato H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 1988, 263:16051-16054.
93. Maeda H., Wu J., Okamoto T., Maruo K., Akaike T. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999, 43:115-128.
94. Marceau F., Bachvarov D.R. Kinin receptors. Clin. Rev. Allergy Immunol. 1998, 16:385-401.
95. Marin-Castano M.E., Schanstra J.P., Neau E., Praddaude F., Pecher C., Ader J.L., Girolami J.P., Bascands J.L. Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation 2002, 105:627-632.
96. Marmarou A., Nichols J., Burgess J., Newell D., Troha J., Burnham D., Pitts L. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma 1999, 16:431-444.
97. Matsumura Y., Kimura M., Yamamoto T., Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 1988, 79:1327-1334.
98. Matsumura Y., Maruo K., Kimura M., Yamamoto T., Konno T., Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res.: Gann 1991, 82:732-741.
99. McFadden R.G., Vickers K.E. Bradykinin augments the in vitro migration of nonsensitized lymphocytes. Clin. Invest Med. 1989, 12:247-253.
100. Menashi S., Fridman R., Desrivieres S., Lu H., Legrand Y., Soria C. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann. N.Y. Acad. Sci. 1994, 732:466-468.
101. Menke J.G., Borkowski J.A., Bierilo K.K., MacNeil T., Derrick A.W., Schneck K.A., Ransom R.W., Strader C.D., Linemeyer D.L., Hess J.F. Expression cloning of a human B1 bradykinin receptor. J. Biol. Chem. 1994, 269:21583-21586.
102. Molina L., Matus C.E., Astroza A., Pavicic F., Tapia E., Toledo C., Perez J.A., Nualart F., Gonzalez C.B., Burgos R.A., Figueroa C.D., Ehrenfeld P., Poblete M.T. Stimulation of the bradykinin B(1) receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res. Treat. 2009, 118:499-510.
103. Montana V., Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J. Neuroscience: Off. J. Soc. Neuroscience 2011, 31:4858-4867.
104. Moodley R., Snyman C., Odhav B., Bhoola K.D. Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. Biol. Chem. 2005, 386:375-382.
105. Morbidelli L., Parenti A., Giovannelli L., Granger H.J., Ledda F., Ziche M. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br. J. Pharmacol. 1998, 124:1286-1292.
106. Moreau M.E., Dubreuil P., Molinaro G., Chagnon M., Muller-Esterl W., Lepage Y., Marceau F., Adam A. Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. J. Pharmacol. Exp. Therap. 2005, 315:1065-1074.
107. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005, 99:6-38.
108. Morissette G., Houle S., Gera L., Stewart J.M., Marceau F. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br. J. Pharmacol. 2007, 150:369-379.
109. Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998, 97:99-107.
110. Naidoo S., Raidoo D.M. Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model. Metab Brain Dis. 2006, 21:253-265.
111. Nardone J., Gerald C., Rimawi L., Song L., Hogan P.G. Identification of a B2 bradykinin receptor expressed by PC12 pheochromocytoma cells. Proc. Natl. Acad. Sci. USA 1994, 91:4412-4416.
112. Narotam P.K., Rodell T.C., Nadvi S.S., Bhoola K.D., Troha J.M., Parbhoosingh R., van Dellen J.R. Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir. 1998, 140:793-802;. (discussion 802-793).
113. Neo J.H., Malcontenti-Wilson C., Muralidharan V., Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J. Gastroenterol. Hepatol. 2007, 22:577-584.
114. Neugebauer W., Blais P.A., Halle S., Filteau C., Regoli D., Gobeil F. Kinin B1 receptor antagonists with multi-enzymatic resistance properties. Can. J. Physiol. Pharmacol. 2002, 80:287-292.
115. Ni A., Chai K.X., Chao L., Chao J. Molecular cloning and expression of rat bradykinin B1 receptor. Biochim. Biophys. Acta 1998, 1442:177-185.
116. Olejek A., Mazurek U., Kusmierz D., Michalska A., Wilczok T. Correlation between the expression of mRNA of histones H2B and H4 and mRNA of kinin receptors B1 and B2 assessed by QRT-PCR in vulvar cancer. Ginekol. Pol. 2002, 73:897-903.
117. Orchel J., Witek L., Kimsa M., Strzalka-Mrozik B., Kimsa M., Olejek A., Mazurek U. Expression patterns of kinin-dependent genes in endometrial cancer. Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc. 2012, 22:937-944.
118. Paegelow I., Lange P. Pharmacological studies on lymphocytes. 1. Effects of 5-hydroxytryptamine, bradykinin, and lymphokines on the migration of lymphocytes in vitro. Agents Actions Suppl. 1982, 10:255-265.
119. Paegelow I., Trzeczak S., Bockmann S., Vietinghoff G. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 2002, 66:153-161.
120. Palmer R.M., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 1988, 333:664-666.
121. Pan Z.K., Zuraw B.L., Lung C.C., Prossnitz E.R., Browning D.D., Ye R.D. Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J. Clin. Invest 1996, 98:2042-2049.
122. Pang L., Knox A.J. PGE2 release by bradykinin in human airway smooth muscle cells: involvement of cyclooxygenase-2 induction. Am. J. Physiol. 1997, 273:L1132-L1140.
123. Papachristopoulou G., Talieri M., Scorilas A. Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med. 2013, 34:369-378.
124. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest 1997, 100:3131-3139.
125. Parenti A., Morbidelli L., Ledda F., Granger H.J., Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001, 15:1487-1489.
126. Parries G., Hoebel R., Racker E. Opposing effects of a ras oncogene on growth factor-stimulated phosphoinositide hydrolysis: desensitization to platelet-derived growth factor and enhanced sensitivity to bradykinin. Proc. Natl. Acad. Sci. USA 1987, 84:2648-2652.
127. Passos G.F., Fernandes E.S., Campos M.M., Araujo J.G., Pesquero J.L., Souza G.E., Avellar M.C., Teixeira M.M., Calixto J.B. Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J. Immunol. 2004, 172:1839-1847.
128. Patel K.J., Tannock I.F. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 2009, 9:356.
129. Pesquero J.B., Araujo R.C., Heppenstall P.A., Stucky C.L., Silva J.A., Walther T., Oliveira S.M., Pesquero J.L., Paiva A.C., Calixto J.B., Lewin G.R., Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. USA 2000, 97:8140-8145.
130. Phagoo S.B., Poole S., Leeb-Lundberg L.M. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol. Pharmacol. 1999, 56:325-333.
131. Prados M.D., Schold S.J.S., Fine H.A., Jaeckle K., Hochberg F., Mechtler L., Fetell M.R., Phuphanich S., Feun L., Janus T.J., Ford K., Graney W. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncology 2003, 5:96-103.
132. Primeau A.J., Rendon A., Hedley D., Lilge L., Tannock I.F. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:8782-8788.
133. Raidoo D.M., Sawant S., Mahabeer R., Bhoola K.D. Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology 1999, 43:255-263.
134. Rastelli V.M., Oliveira M.A., dos Santos R., de Cassia Tostes Passaglia R., Nigro D., de Carvalho M.H., Fortes Z.B. Enalapril treatment corrects the reduced response to bradykinin in diabetes increasing the B2 protein expression. Peptides 2008, 29:404-411.
135. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980, 32:1-46.
136. Regoli D., Barabe J., Park W.K. Receptors for bradykinin in rabbit aortae. Can. J. Physiol. Pharmacol. 1977, 55:855-867.
137. Ribeiro-Oliveira A., Franchi G., Kola B., Dalino P., Pinheiro S.V., Salahuddin N., Musat M., Goth M.I., Czirjak S., Hanzely Z., da Silva D.A., Paulino E., Grossman A.B., Korbonits M. Protein western array analysis in human pituitary tumours: insights and limitations. Endocrinol. Relat. Cancer 2008, 15:1099-1114.
138. Roberts R.A. Bradykinin receptors: characterization, distribution and mechanisms of signal transduction. Prog. Growth Factor Res. 1989, 1:237-252.
139. Roberts R.A., Gullick W.J. Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J. Cell Sci. 1989, 94(Pt 3):527-535.
140. Rocha E.S., Beraldo W.T., Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am. J. Physiol. 1949, 156:261-273.
141. Rodrigues E.S., Silva R.F., Martin R.P., Oliveira S.M., Nakaie C.R., Sabatini R.A., Merino V.F., Pesquero J.B., Bader M., Shimuta S.I. Evidence that kinin B(2) receptor expression is upregulated by endothelial overexpression of B(1) receptors. Peptides 2013.
142. Ruggiero M., Srivastava S.K., Fleming T.P., Ron D., Eva A. NIH3T3 fibroblasts transformed by the dbl oncogene show altered expression of bradykinin receptors: effect on inositol lipid turnover. Oncogene 1989, 4:767-771.
143. Sakamoto W., Kaga M., Handa H., Gotoh K., Suzuki S., Fujie K., Inoue N., Nishihira J. Bradykinin and Met-T-kinin-Leu stimulated PGE2 production by rat macrophage and fibroblast. Braz. J. Med. Biol. Res. 1994, 27:1923-1927.
144. Saleh T.S., Calixto J.B., Medeiros Y.S. Pro-inflammatory effects induced by bradykinin in a murine model of pleurisy. Eur. J. Pharmacol. 1997, 331:43-52.
145. Santos D.R., Calixto J.B., Souza G.E. Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats. Br. J. Pharmacol. 2003, 139:271-278.
146. Sawant S., Snyman C., Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int. Immunopharmacol. 2001, 1:2063-2080.
147. Schanstra J.P., Bataille E., Marin Castano M.E., Barascud Y., Hirtz C., Pesquero J.B., Pecher C., Gauthier F., Girolami J.P., Bascands J.L. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J. Clin. Invest. 1998, 101:2080-2091.
148. Schlemper V., Calixto J.B. Nitric oxide pathway-mediated relaxant effect of bradykinin in the guinea-pig isolated trachea. Br. J. Pharmacol. 1994, 111:83-88.
149. Schulze-Topphoff U., Prat A., Prozorovski T., Siffrin V., Paterka M., Herz J., Bendix I., Ifergan I., Schadock I., Mori M.A., Van H.J., Schroter F., Smorodchenko A., Han M.H., Bader M., Steinman L., Aktas O., Zipp F. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med. 2009, 15:788-793.
150. Sevcik M.A., Ghilardi J.R., Halvorson K.G., Lindsay T.H., Kubota K., Mantyh P.W. Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. J. Pain 2005, 6:771-775.
151. Sgnaolin V., Pereira T.C., Bogo M.R., Zanin R., Battastini A.M., Morrone F.B., Campos M.M. Functional and molecular characterization of kinin B(1) and B(2) receptors in human bladder cancer: implication of the PI3Kgamma pathway. Invest. New Drugs 2012.
152. Shakur H., Andrews P., Asser T., Balica L., Boeriu C., Quintero J.D., Dewan Y., Druwe P., Fletcher O., Frost C., Hartzenberg B., Mantilla J.M., Murillo-Cabezas F., Pachl J., Ravi R.R., Ratsep I., Sampaio C., Singh M., Svoboda P., Roberts I. The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009, 10:109.
153. Sharma J.N., Al-Dhalmawi G.S. Bradykinin receptor antagonists: therapeutic implications. IDrugs 2003, 6:581-586.
154. Skeggs L.T., Kahn J.R., Shumway N.P. The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 1956, 103:295-299.
155. Skeggs L.T., Marsh W.H., Kahn J.R., Shumway N.P. The existence of two forms of hypertensin. J. Exp. Med. 1954, 99:275-282.
156. Spinetti G., Fortunato O., Cordella D., Portararo P., Krankel N., Katare R., Sala-Newby G.B., Richer C., Vincent M.P., Alhenc-Gelas F., Tonolo G., Cherchi S., Emanueli C., Madeddu P. Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ. Res. 2011, 108:284-293.
157. Stefanidakis M., Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006, 108:1441-1450.
158. Stewart J.M. Bradykinin antagonists: discovery and development. Peptides 2004, 25:527-532.
159. Stewart J.M., Gera L., Chan D.C., Bunn P.A., York E.J., Simkeviciene V., Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. Can. J. Physiol. Pharmacol. 2002, 80:275-280.
160. Stewart J.M., Gera L., York E.J., Chan D.C., Whalley E.J., Bunn P.A., Vavrek R.J. Metabolism-resistant bradykinin antagonists: development and applications. Biol. Chem. 2001, 382:37-41.
161. Su J.B. Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems. J. Renin-Angiotensin-Aldosterone Syst., JRAAS 2013.
162. Tanabe A., Shiraishi M., Negishi M., Saito N., Tanabe M., Sasaki Y. MARCKS dephosphorylation is involved in bradykinin-induced neurite outgrowth in neuroblastoma SH-SY5Y cells. J. Cell. Physiol. 2012, 227:618-629.
163. Taub J.S., Guo R., Leeb-Lundberg L.M., Madden J.F., Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 2003, 63:2037-2041.
164. Thomas S.M., Bhola N.E., Zhang Q., Contrucci S.C., Wentzel A.L., Freilino M.L., Gooding W.E., Siegfried J.M., Chan D.C., Grandis J.R. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006, 66:11831-11839.
165. Tiffany C.W., Burch R.M. Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett. 1989, 247:189-192.
166. Toledo C., Matus C.E., Barraza X., Arroyo P., Ehrenfeld P., Figueroa C.D., Bhoola K.D., Del Pozo M., Poblete M.T. Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. World J. Gastroenterol.: WJG 2012, 18:1208-1215.
167. Trifilieff A., Lach E., Dumont P., Gies J.P. Bradykinin binding sites in healthy and carcinomatous human lung. Br. J. Pharmacol. 1994, 111:1228-1232.
168. Tschesche H., Michaelis J., Kohnert U., Fedrowitz J., Oberhoff R. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv. Exp. Med. Biol. 1989, 247A:545-548.
169. Tsutsumi Y., Matsubara H., Masaki H., Kurihara H., Murasawa S., Takai S., Miyazaki M., Nozawa Y., Ozono R., Nakagawa K., Miwa T., Kawada N., Mori Y., Shibasaki Y., Tanaka Y., Fujiyama S., Koyama Y., Fujiyama A., Takahashi H., Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 1999, 104:925-935.
170. van Winden A.W., Gast M.C., Beijnen J.H., Rutgers E.J., Grobbee D.E., Peeters P.H., van Gils C.H. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med. Genomics 2009, 2:4.
171. Vassou D., Notas G., Hatzoglou A., Castanas E., Kampa M. Opioids increase bladder cancer cell migration via bradykinin B2 receptors. Int. J. Oncol. 2011, 39:697-707.
172. Vavrek R.J., Stewart J.M. Competitive antagonists of bradykinin. Peptides 1985, 6:161-164.
173. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., Fleisher M., Lilja H., Brogi E., Boyd J., Sanchez-Carbayo M., Holland E.C., Cordon-Cardo C., Scher H.I., Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116:271-284.
174. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., Molteni A., Polverini P.J., Bouck N.P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996, 98:671-679.
175. Wang D.Z., Chao L., Chao J. Cellular localization of bradykinin B1 receptor mRNA in the human kidney. Immunopharmacology 1996, 33:151-156.
176. Wang J.W., Su W., Law Y.P., Lu C.H., Chen Y.C., Wang J.L., Chang H.J., Chen W.C., Jan C.R. Mechanism of bradykinin-induced Ca(2+) mobilization in MG63 human osteosarcoma cells. Horm. Res. 2001, 55:265-270.
177. Wang P.H., Campanholle G., Cenedeze M.A., Feitoza C.Q., Goncalves G.M., Landgraf R.G., Jancar S., Pesquero J.B., Pacheco-Silva A., Camara N.O. Bradykinin [corrected] B1 receptor antagonism is beneficial in renal ischemia-reperfusion injury. PLoS One 2008, 3:e3050.
178. Wang P.H., Cenedeze M.A., Campanholle G., Malheiros D.M., Torres H.A., Pesquero J.B., Pacheco-Silva A., Camara N.O. Deletion of bradykinin B1 receptor reduces renal fibrosis. Int. Immunopharmacol. 2009, 9:653-657.
179. Warren K., Jakacki R., Widemann B., Aikin A., Libucha M., Packer R., Vezina G., Reaman G., Shaw D., Krailo M., Osborne C., Cehelsky J., Caldwell D., Stanwood J., Steinberg S.M., Balis F.M. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother. Pharmacol. 2006, 58:343-347.
180. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl. Cancer Inst. 2009, 101:1325-1329.
181. Wen S.W., Ager E.I., Neo J., Christophi C. The renin angiotensin system regulates Kupffer cells in colorectal liver metastases. Cancer Biol. Ther. 2013, 14:720-727.
182. Whalley E.T., Figueroa C.D., Gera L., Bhoola K.D. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin. Drug Discov. 2012, 7:1129-1148.
183. Wotherspoon G., Winter J. Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci. Lett. 2000, 294:175-178.
184. Wu J., Akaike T., Hayashida K., Miyamoto Y., Nakagawa T., Miyakawa K., Muller-Esterl W., Maeda H. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int. J. Cancer 2002, 98:29-35.
185. Yang W.H., Chang J.T., Hsu S.F., Li T.M., Cho D.Y., Huang C.Y., Fong Y.C., Tang C.H. Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways. J. Cell Biochem. 2010, 109:82-92.
186. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Fukui H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2001, 7:1073-1078.
187. Yu H.S., Lin T.H., Tang C.H. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCdelta/c-Src dependent signaling pathway. Prostate 2013, 73:89-100.
188. Yu H.S., Lin T.H., Tang C.H. Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers. Int. J. Mol. Sci. 2013, 14:13329-13345.
189. Zelawski W., Machnik G., Nowaczyk G., Plewka D., Lorenc Z., Sosada K., Stadnicki A. Expression and localisation of kinin receptors in colorectal polyps. Int. Immunopharmacol. 2006, 6:997-1002.
190. Zhang R., Shi H., Chen Z., Feng W., Zhang H., Wu K. Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells. Mol. Med. Rep. 2012, 5:256-259.
191. Zhang W., Bhola N., Kalyankrishna S., Gooding W., Hunt J., Seethala R., Grandis J.R., Siegfried J.M. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol. Cancer Res. 2008, 6:1946-1956.
192. Zhang X., Tan F., Brovkovych V., Zhang Y., Lowry J.L., Skidgel R.A. Carboxypeptidase M augments kinin B1 receptor signaling by conformational crosstalk and enhances endothelial nitric oxide output. Biol. Chem. 2013, 394:335-345.
193. Zhang X., Tan F., Brovkovych V., Zhang Y., Skidgel R.A. Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J. Biol. Chem. 2011, 286:18547-18561.
194. Zhang X., Tan F., Skidgel R.A. Carboxypeptidase m is a positive allosteric modulator of the kinin b1 receptor. J. Biol. Chem. 2013, 288:33226-33240.
195. Zhao B., Maruo S., Cooper A., Chase M.R., Johannsen E., Kieff E., Cahir-McFarland E. RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. Proc. Natl. Acad. Sci. USA 2006, 103:1900-1905.
196. Zisman L.S. Inhibiting tissue angiotensin-converting enzyme: a pound of flesh without the blood?. Circulation 1998, 98:2788-2790.